Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

Autologous platelet-rich plasma treatment for moderate-severe Asherman syndrome: the first experience. Journal of assisted reproduction and genetics Aghajanova, L., Sundaram, V., Kao, C., Letourneau, J. M., Manvelyan, E., Cedars, M. I., Huddleston, H. G. 2021

Abstract

PURPOSE: Treatment of Asherman syndrome (AS) presents a significant clinical challenge. Based on our in vitro data showing that PRP could activate endometrial cell proliferation and migration, we hypothesized that intrauterine infusion of autologous platelet-rich plasma (PRP) may improve endometrial regeneration and fertility outcomes in patients with moderate-severe AS.MATERIALS AND METHODS: Subjects with moderate-severe AS were randomized to PRP or saline control administered following hysteroscopic adhesiolysis. Due to relative inability to randomize patients to the control group, after initial randomization of 10 subjects (6 in PRP and 4 in control groups), the remainder were prospectively enrolled in PRP group (n=9), with 11 historic controls added to control group, for a total of 30 subjects (PRP n=15; saline control n=15). Right after hysteroscopy, 0.5-1mL of PRP or saline was infused into the uterus via a Wallace catheter, followed by estrogen therapy. The primary outcomes were changes in endometrial thickness (EMT, checked in 3weeks) and in menstrual flow; secondary outcomes were pregnancy and live birth rates. EMT and menstrual bleeding pattern were assessed before and after the intervention. Pregnancy was assessed over a 6-month period.RESULTS: There were no statistically significant differences in age, gravidity/parity, cause of AS, preoperative menses assessment, AS hysteroscopy score, and intrauterine balloon placement between the groups. There was no statistically significant difference (p=0.79) in EMT pre-PRP infusion for control (5.7mm, 4.0-6.0) and study arm (5.3mm, 4.9-6.0). There was no statistically significant change (p=0.78) in EMT after PRP infusion (1.4mm,-0.5-2.4) vs saline (1.0mm, 0.0-2.5). Patients tolerated the procedure well, with no adverse effects. There was no difference in the predicted likelihood of pregnancy (p=0.45) between the control (0.67, 0.41-0.85) and study arm (0.53, 0.29-0.76).CONCLUSIONS: PRP was well accepted and tolerated in AS patients. However, we did not observe any significant EMT increase or improved pregnancy rates after adding PRP infusion, compared to standard treatment only. The use of intrauterine PRP infusion may be a feasible option, and its potential use must be tested on a larger sample size of AS patients.

View details for DOI 10.1007/s10815-021-02328-5

View details for PubMedID 34613578